Biosergen AB
STO:BIOSGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Biosergen AB
Total Assets
Biosergen AB
Total Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Biosergen AB
STO:BIOSGN
|
Total Assets
kr53m
|
CAGR 3-Years
15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Total Assets
kr1.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Total Assets
kr1B
|
CAGR 3-Years
41%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Total Assets
kr11.1B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
37%
|
CAGR 10-Years
27%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Total Assets
kr67.4B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
23%
|
|
|
BioArctic AB
STO:BIOA B
|
Total Assets
kr2.6B
|
CAGR 3-Years
44%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
Biosergen AB
Glance View
Biosergen AB operates as a biopharmaceutical company. The company is headquartered in Solna, Stockholm. The company went IPO on 2021-06-24. The company carries out biopharmaceutical research and development through its Subsidiary Biosergen AS from laboratory facilities in Trondheim, Norway and several other places worldwide. The firm is developing BSG005, a potentially disruptive antifungal drug which has demonstrated safety and potency advantages over competing antifungals. Biosergen initially aims BSG005 towards invasive fungal infections that claim the lives of hundreds of thousands of immune-compromised AIDS, cancer and transplant patients every year. At equal dose levels BSG005 has demonstrated a three-to-fouold potency advantage against the relevant fungal strains compared to the current standard of care, while being completely free of the kidney toxicity hampering other drugs in its class.
See Also
What is Biosergen AB's Total Assets?
Total Assets
7.2m
SEK
Based on the financial report for Dec 31, 2023, Biosergen AB's Total Assets amounts to 7.2m SEK.
What is Biosergen AB's Total Assets growth rate?
Total Assets CAGR 3Y
15%
Over the last year, the Total Assets growth was -79%. The average annual Total Assets growth rates for Biosergen AB have been 15% over the past three years .
